# Mite Asthma Pediatric Immunotherapy Trial

> **NCT03654976** · PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 533 (actual)

## Conditions studied

- Allergic Asthma Due to Dermatophagoides Farinae
- Allergic Asthma Due to Dermatophagoides Pteronyssinus
- Allergic Rhinitis Due to House Dust Mite

## Interventions

- **BIOLOGICAL:** HDM SLIT-tablet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03654976
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-22
- **Primary completion:** 2022-05-18
- **Final completion:** 2022-05-31
- **Target enrollment:** 533 (ACTUAL)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654976, "Mite Asthma Pediatric Immunotherapy Trial". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03654976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*